Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28745297 | 0.78 | S100A9 (0.31) | KDM4E | |
| SCHEMBL20508396 | 0.74 | — | — | |
| SCHEMBL29201427 | 0.73 | KMT2A (0.31) | KMT2A | |
| SCHEMBL22468721 | 0.71 | KDM4E (0.31) | KDM4EMAPTRECQLPOLBMEN1 | |
| SCHEMBL17080244 | 0.71 | SMN1; SMN2 (0.44) | KDM4EMAPTMEN1KMT2A | |
| SCHEMBL27843286 | 0.70 | ALDH1A1 (0.45) | KDM4EMAPTPOLBMEN1KMT2A | |
| SCHEMBL29271395 | 0.70 | NFE2L2 (0.40) | — | |
| SCHEMBL3713535 | 0.70 | MMP2 (0.39) | — | |
| SCHEMBL31328880 | 0.70 | MMP2 (0.39) | — | |
| SCHEMBL22468700 | 0.69 | MMP2 (0.33) | KDM4EMAPTRECQLPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230078913-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS | ESSA PHARMA INC. (CA) | 2023-03-16 | — | — | US | disclosed |
| EP-3946292-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS | Essa Pharma, Inc. (CA) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020198711-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS | ESSA PHARMA, INC. (CA) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078913-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS | AR, PSMA1, SHBG | KDM4E 1622/4885MAPT 2333/4885RECQL 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.